MARKET

SAVA

SAVA

Cassava Sciences Inc
NASDAQ
41.82
-1.25
-2.90%
After Hours: 42.00 +0.18 +0.43% 19:58 09/30 EDT
OPEN
42.63
PREV CLOSE
43.07
HIGH
44.80
LOW
41.08
VOLUME
2.04M
TURNOVER
0
52 WEEK HIGH
100.00
52 WEEK LOW
13.84
MARKET CAP
1.68B
P/E (TTM)
-27.5949
1D
5D
1M
3M
1Y
5Y
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock.
Benzinga · 2d ago
Cassava Sciences, Inc. (SAVA) Stock Moves -1.76%: What You Should Know
Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $43.07, moving -1.76% from the previous trading session.
Zacks · 2d ago
Many Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai data
Biogen (NASDAQ:BIIB) and Eisai (<a href="https://seekingalpha.com/symbol/ES...
Seekingalpha · 3d ago
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Benzinga · 3d ago
Why Is Acumen (ABOS) Stock Up 95% Today?
Investor Place · 3d ago
What Is Going on With Silo Pharma (SILO) Stock Today?
Investor Place · 4d ago
Why Is Taiwan Semiconductor (TSM) Stock Down Today?
Investor Place · 4d ago
Why Is Cassava Sciences (SAVA) Stock Heating Up Today?
Investor Place · 4d ago
More
About SAVA
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is primarily focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimer's disease. The Company develops pharmaceutical product candidates that offer improvements to patients and healthcare professionals. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. The Company is conducting a Phase III program with Simufilam in patients with mild-to-moderate Alzheimer’s disease dementia. Its investigational product candidate, SavaDx, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. SavaDx is designed as an antibody-based detection system for altered filamin A (FLNA).

Webull offers kinds of Cassava Sciences Inc stock information, including NASDAQ:SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.